- Previous Close
79.36 - Open
80.85 - Bid --
- Ask --
- Day's Range
77.81 - 87.60 - 52 Week Range
75.20 - 171.90 - Volume
79,486 - Avg. Volume
89,821 - Market Cap (intraday)
3.695B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.94 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopoeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.
valiantlabs.in77
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: VALIANTLAB.NS
View MorePerformance Overview: VALIANTLAB.NS
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VALIANTLAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VALIANTLAB.NS
View MoreValuation Measures
Market Cap
3.44B
Enterprise Value
3.41B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.25
Price/Book (mrq)
1.49
Enterprise Value/Revenue
3.21
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-3.90%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.06B
Net Income Avi to Common (ttm)
-41.44M
Diluted EPS (ttm)
-0.94
Balance Sheet and Cash Flow
Total Cash (mrq)
1.19B
Total Debt/Equity (mrq)
49.90%
Levered Free Cash Flow (ttm)
--